Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.

about

Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.

Item

http://www.wikidata.org/entity/Q38614592

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.

@en

type

Item

label

Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.

@en

prefLabel

Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.

@en

P1476

Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection

@en

P2093

Abdus Sattar

http://www.w3.org/2001/XMLSchema#string

Grace A McComsey

http://www.w3.org/2001/XMLSchema#string

Manjusha Kulkarni

http://www.w3.org/2001/XMLSchema#string

Sahera Dirajlal-Fargo

http://www.w3.org/2001/XMLSchema#string

P2860

Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3

Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin

TWEAK attenuates the transition from innate to adaptive immunity

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.

A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications.

Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.

Soluble TWEAK independently predicts atherosclerosis in renal transplant patients.

P304

156-163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15284336.2017.1366001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas Funderburg

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28828963

http://www.w3.org/2001/XMLSchema#string